Laboratory of Experimental and Translational Oncology, Department of Oncology, Microbiology and Immunology, Faculty of Science and Medicine, University of Fribourg, Chemin Du Musée 18, PER17, 1700, Fribourg, Switzerland; NCCR Bio-inspired Materials, University of Fribourg, 1700, Fribourg, Switzerland.
Laboratory of Experimental and Translational Oncology, Department of Oncology, Microbiology and Immunology, Faculty of Science and Medicine, University of Fribourg, Chemin Du Musée 18, PER17, 1700, Fribourg, Switzerland; NCCR Bio-inspired Materials, University of Fribourg, 1700, Fribourg, Switzerland; Cell Analytics Facility, Faculty of Science and Medicine, University of Fribourg, Chemin Du Musée 18, PER17, 1700, Fribourg, Switzerland.
Biosens Bioelectron. 2025 Jan 1;267:116839. doi: 10.1016/j.bios.2024.116839. Epub 2024 Oct 5.
The detection of cancer-associated nucleic acids and mutations through liquid biopsy has emerged as a highly promising non-invasive approach for early cancer detection and monitoring. In this study, we report the development of primer exchange reaction (PER) based signal amplification strategy that enables the rapid, sensitive and specific detection of nucleic acids bearing cancer specific single nucleotide mutations using flow cytometry. Using micrometer size beads as support for immobilizing oligonucleotides and programmable PER assembly for target oligonucleotide recognition and fluorescence signal amplification, we demonstrated the versatile detection of target nucleic acids including KRAS oligonucleotide, fragmented mRNAs, and miR-21. Moreover, our detection system can discriminate single base mutations frequently occurred in cancer-associated genes including KRAS, PIK3CA and P53 from cell extracts and circulating tumor DNAs (ctDNAs). The detection is highly sensitive, with a limit of detection down to 27 fM without pre-amplification. In view of a clinical application, we demonstrate the detection of single mutations after extraction and pre-amplification of ctDNAs from the plasma of breast cancer patients. Importantly, our detection strategy enabled the detection of single KRAS mutation even in the presence of 1000-fold excess of wild type (WT) DNA using multi-color flow cytometry detection approach. Overall, our strategy holds immense potential for clinical applications, offering significant improvements for early cancer detection and monitoring.
通过液体活检检测与癌症相关的核酸和突变已成为一种极具前景的非侵入性早期癌症检测和监测方法。在这项研究中,我们报告了一种基于引物交换反应(PER)的信号放大策略的发展,该策略可通过流式细胞术快速、敏感和特异性地检测带有癌症特异性单核苷酸突变的核酸。我们使用微米大小的珠子作为固定寡核苷酸的支持物,并可编程 PER 组装来识别靶寡核苷酸和荧光信号放大,从而证明了目标核酸的多功能检测,包括 KRAS 寡核苷酸、碎片化的 mRNAs 和 miR-21。此外,我们的检测系统能够从细胞提取物和循环肿瘤 DNA(ctDNA)中区分出包括 KRAS、PIK3CA 和 P53 在内的癌症相关基因中经常发生的单碱基突变。检测非常灵敏,无需预扩增即可达到 27 fM 的检测限。鉴于临床应用,我们证明了从乳腺癌患者血浆中提取和预扩增 ctDNA 后,单突变的检测。重要的是,我们的检测策略即使在存在 1000 倍过量野生型(WT)DNA 的情况下,也能够通过多色流式细胞术检测方法检测到单个 KRAS 突变。总的来说,我们的策略具有巨大的临床应用潜力,为早期癌症检测和监测提供了显著的改进。